Today: 10 April 2026
Subscribe
Browse Category

Health News 5 January 2026 - 19 March 2026

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure shares jumped 23% to $12.91 in U.S. premarket trading Thursday after the FDA approved its Optune Pax device for locally advanced pancreatic cancer. The company said this is the first new FDA-approved treatment for the disease in nearly 30 years. In a Phase 3 trial, median overall survival was 16.2 months with Optune Pax plus chemotherapy, compared to 14.2 months with chemotherapy alone.
12 February 2026
·
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk B shares rose 5.29% to 295.50 Danish crowns Friday after Hims & Hers said it would stop selling a $49 compounded version of Novo’s Wegovy pill. The rebound followed a steep two-day drop and came as the FDA pledged action against mass-marketed copycats. The stock remains down about 20% over five sessions. Investors remain uncertain about Novo’s patent protections and future pricing power.
8 February 2026
···
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
1 2 3

Stock Market Today

  • ISS Climate Vote Shines Spotlight on BP's Valuation and Climate Reporting
    April 9, 2026, 9:22 PM EDT. Proxy adviser ISS recommends BP shareholders oppose retiring two climate reporting resolutions from 2015 and 2019, intensifying focus on BP's climate disclosures ahead of its AGM. BP, a global energy firm operating in oil, gas, and low carbon sectors, faces increased scrutiny on its emissions and transition plans amid growing investor pressure. The vote could shape future climate transparency and shareholder engagement. BP shares trade slightly above analyst targets but remain undervalued by about 71%, signaling a significant valuation gap. With a 30-day return of 16.2%, investor sentiment shows support before the climate vote. Key risks include a razor-thin profit margin of 0.03%, complicating the balance between climate investments and profitability. The AGM outcome is pivotal for BP's governance and long-term climate strategy.

Latest article

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Go toTop